Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Low-dose oral minoxidil increases hair density and thickness in people with hair loss.

This article discusses the potential use of platelet-rich plasma as a treatment for vitiligo, but reports no new clinical results; further investigation is needed.

This article outlines treatment options and counseling recommendations for pediatric alopecia areata, highlighting shared decision-making based on disease severity and patient goals, with newer treatments like JAK inhibitors and dupilumab requiring attention to cost and side effects.

This article contains no new research findings and does not create or analyze any new data.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.

This study found that finasteride treatment in male rats may lead to changes in connexin 43 expression in the testes of their offspring, potentially affecting spermatogenesis.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

In this study of women with frontal fibrosing alopecia, delgocitinib cream improved the molecular signature of lesions and demonstrated potential as a treatment, showing significant transcriptomic changes and some clinical improvements over 12 weeks compared to a cream vehicle.

This study found that watching educational videos from a social media video library significantly improved patients' knowledge of hair loss disorders.

This article discusses various limitations of direct-to-consumer teledermatology platforms, highlighting concerns regarding ethical issues, financial conflicts of interest, and challenges in providing comprehensive patient care compared to traditional in-person consultations.

This article reviews a new method to accurately estimate proliferative and migratory epithelial cell numbers post-wounding but reports no experimental findings; the authors suggest its relevance to skin stem-cell biology research.

This article reviews the multifaceted roles of adipose tissue in skin biology and highlights its potential implications for epidermal homeostasis and wound healing; it reports no new research findings.

In this study, US-based experts reached a consensus on treating adults with severe alopecia areata, recommending oral Janus kinase inhibitors as the primary long-term therapy, while also suggesting supplemental treatments like minoxidil and corticosteroids, with a call for more research on specific patient subpopulations.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

This study found that women with central centrifugal cicatricial alopecia had a substantial prevalence of systemic comorbidities, including strong associations with dyslipidemia, uterine leiomyomas, and anxiety disorders.

This study reviewed evidence on cutaneous reactions and associated radiation doses from cranial or spinal neurointerventional procedures, finding that alopecia/epilation was most common and onset doses often aligned with known thresholds, highlighting the need for standardized dose reporting and follow-up.

This registry-based analysis observed rapid growth in hair-loss clinical trials between 2015 and 2025, highlighting regional concentration, prevalent therapeutic categories, and diverse outcome reporting while emphasizing the need for standardization and broader representation.

This study analyzed hair-loss clinical trials from 2015 to 2025 and found that, while the number of registrations increased globally, research activity was concentrated in certain regions and varied in therapeutic approaches and outcome specifications.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

In this single-cell transcriptomic study, researchers analyzed AA scalp samples and found distinct immune and nonimmune cell activation patterns, with elevated TH1/TH2 and JAK/STAT markers potentially contributing to hair follicle immune privilege disruption and disease severity.

In this case study, a 14-year-old boy with treatment-resistant diffuse alopecia areata achieved complete hair regrowth following three monthly sessions of microneedling combined with injections of triamcinolone, dutasteride, and synthetic exosomes, suggesting that exosome-based therapy could be a promising alternative for managing refractory autoimmune alopecia.

This study reports on a 14-year-old male with refractory diffuse alopecia areata who achieved full hair density restoration after three monthly sessions of microneedling combined with triamcinolone, dutasteride, and synthetic exosome treatment, highlighting exosomes' potential for enhancing traditional therapies in autoimmune hair loss cases.

This review discusses androgenetic alopecia, outlining its genetic and hormonal causes, and summarizes current and emerging treatments like minoxidil, finasteride, and low-dose oral therapies, emphasizing the need for more research to confirm the efficacy and safety of newer approaches.

This review explores the management of facial hair in active-duty female military members, focusing on conditions like pseudofolliculitis barbae and hirsutism, and underscores the importance for healthcare practitioners to understand the psychosocial and medical aspects of these conditions in both military and civilian contexts.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

In this systematic review, the researchers provide an overview of recent techniques and innovations in the surgical reconstruction of traumatic scalp injuries, highlighting various methods and factors influencing the choice of reconstructive strategy to improve patient outcomes.

This study identified changes in immune activation, ferroptosis, and structural genes in alopecia areata subtypes, suggesting molecular markers that might help understand disease variability and guide future treatments.